Breaking News, Financial News

AstraZeneca 3Q

Sales of Influenza A (H1N1) vaccine totaled $152 million in the quarter. Nexium sales were down 5% to $1.2 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 3Q09 3Q Revenues: $8.2 billion (+5%) 3Q Earnings: $2.1 billion (+27%) YTD Revenues: $23.9 billion (+2%) YTD Earnings: $6.0 billion (+27%) Comments: Sales of Influenza A (H1N1) vaccine totaled $152 million in the quarter. Nexium sales were down 5% to $1.2 billion. Crestor sales were $1.1 billion (+24%). Seloken /Toprol-XL sales were $414 million (+103%). Symbicort sales were $562 million (+12%). Seroquel sales were $1.2 billion (+9%). Casodex sales in the U.S. were down...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters